The abstract is read at the publisher; the summary is JClub's.
RASA2 is consistently upregulated in KRAS-mutant pancreatic ductal adenocarcinoma and is linked to poor prognosis and metastatic progression, implicating it in PDAC aggressiveness.
- Why it matters: KRAS-driven PDAC still lacks targeted strategies to block metastasis, and the role of RASA2 in tumor progression and its underlying signaling mechanism is unclear.
- What they did: The study combined integrative dataset/clinical-sample analyses with gain- and loss-of-function assays in KRAS-mutant and KRAS-wild-type models, then used transcriptomic and mechanistic work to connect RASA2 to TGFβ2-dependent non-canonical Hedgehog signaling via GLI1.
- The result: Inhibiting TGFβ signaling or silencing GLI1 suppressed RASA2-driven migration, invasion, and metastasis in vitro and in vivo, nominating the RASA2–TGFβ2–GLI1 axis as a potential therapeutic target in PDAC.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.